PROLEUKIN 18 millions U.I.

DRUG2 trials

Sponsors

Cellectis, Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Conditions

Alzheimer DiseaseRelapsed or refractory B-cell Non-Hodgkin lymphoma

Phase 1

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

RecruitingCTIS2022-501607-27-00

CellectisRelapsed or refractory B-cell Non-Hodgkin lymphoma

Start: 2026-01-06Target: 48Updated: 2026-01-08

Phase 2

Therapeutic evaluation of low-dose IL-2-based immunomodulatory approach in patients with early AD

Not yet recruitingCTIS2024-516565-36-00

Groupe Hospitalier Universitaire Paris Psychiatrie Et NeuroscienceAlzheimer Disease

Target: 45Updated: 2025-06-13